Table 1. Clinical and molecular data of the young adult glioblastoma cohort.
| n = 107 | |
|---|---|
| Gender (Male/Female) | 66/41 |
| Age (Mean/median/range) | 25.0/25/(17–35) |
| Tumor location | |
| Cerebral hemisphere | 65 (60.7%) |
| Cerebellum | 1 (0.9%) |
| Midline structures | 18 (16.8%) |
| More than one location affected | 23 (21.5%) |
| Operation | |
| Total resection | 58 (54.2%) |
| Non-total resection | 29 (27.1%) |
| Not available | 20 (18.7%) |
| Adjuvant therapy | |
| Radiotherapy + chemotherapy | 52 (48.6%) |
| Radiotherapy only | 9 (8.4%) |
| Chemotherapy only | 12 (11.2%) |
| No adjuvant therapy | 7 (6.5%) |
| Not available | 27 (25.2%) |
| BRAF | |
| Mutant | 16 (15%) |
| Wild-type | 91 (85%) |
| IDH1 | |
| Mutant | 18 (16.8%) |
| Wild-type | 89 (83.2%) |
| H3F3A | |
| K27M | 17 (15.9%) |
| G34R/V | 3 (2.8%) |
| wild-type | 87 (81.3%) |
| HIST1H3B | |
| Mutant | 0 (0%) |
| wild-type | 107 (100%) |
| EGFR | |
| Amplified | 4 (3.7%) |
| Non-amplified | 103 (96.3%) |
| TERTp | |
| C228T mutant | 6 (5.6%) |
| C250T mutant | 3 (2.8%) |
| Wild-type | 95 (88.8%) |
| Not available | 3 (2.8%) |
| CDKN2A homozygous deletion | |
| Yes | 31 (29%) |
| No | 56 (52.3%) |
| Not available | 20 (18.7%) |
| PDGFRA expression | |
| Positive | 33 (30.8%) |
| Negative | 74 (69.2%) |